These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38989145)

  • 1. BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models.
    Guffanti F; Mengoli I; Alvisi MF; Dellavedova G; Giavazzi R; Fruscio R; Rulli E; Damia G
    Front Pharmacol; 2024; 15():1390116. PubMed ID: 38989145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Guffanti F; Alvisi MF; Anastasia A; Ricci F; Chiappa M; Llop-Guevara A; Serra V; Fruscio R; Degasperi A; Nik-Zainal S; Bani MR; Lupia M; Giavazzi R; Rulli E; Damia G
    Br J Cancer; 2022 Jan; 126(1):120-128. PubMed ID: 34732853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
    Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
    J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Velazquez C; Orhan E; Tabet I; Fenou L; Orsetti B; Adélaïde J; Guille A; Thézénas S; Crapez E; Colombo PE; Chaffanet M; Birnbaum D; Sardet C; Jacot W; Theillet C
    Front Oncol; 2023; 13():1125021. PubMed ID: 37007122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homologous recombination deficiency real-time clinical assays, ready or not?
    Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
    Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assays for assessment of homologous recombination DNA repair deficiency.
    Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
    Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 10. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis.
    Batalini F; DaSilva LL; Campoverde L; Comini ACM; Carvalho BM; Nogueira W; Silveira H; Ernst BJ; Mina LA
    Chin Clin Oncol; 2023 Jun; 12(3):21. PubMed ID: 37211773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
    Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    Castroviejo-Bermejo M; Cruz C; Llop-Guevara A; Gutiérrez-Enríquez S; Ducy M; Ibrahim YH; Gris-Oliver A; Pellegrino B; Bruna A; Guzmán M; Rodríguez O; Grueso J; Bonache S; Moles-Fernández A; Villacampa G; Viaplana C; Gómez P; Vidal M; Peg V; Serres-Créixams X; Dellaire G; Simard J; Nuciforo P; Rubio IT; Dienstmann R; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Déas O; Jonkers J; Masson JY; Cairo S; Judde JG; O'Connor MJ; Díez O; Balmaña J; Serra V
    EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30377213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
    Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
    Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
    BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    Pujade-Lauraine E; Brown J; Barnicle A; Wessen J; Lao-Sirieix P; Criscione SW; du Bois A; Lorusso D; Romero I; Petru E; Yoshida H; Vergote I; Colombo N; Hietanen S; Provansal M; Schmalfeldt B; Pignata S; Martín Lorente C; Berton D; Runnebaum IB; Ray-Coquard I
    JCO Precis Oncol; 2023 Jan; 7():e2200258. PubMed ID: 36716415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.